Trial Results, Patient Enrollment, and Strategic Collaborations - Analyst Notes on Alnylam, Celldex, Keryx, Spectrum and MacroGenics
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, June 12, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and MacroGenics, Inc. (NASDAQ: MGNX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3634-100free.
--
Alnylam Pharmaceuticals, Inc. Analyst Notes
On June 9, 2014, Alnylam Pharmaceuticals, Inc. (Alnylam) announced pre-clinical results with its Development Candidate (DC) for ALN-CC5. ALN-CC5 is a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases. According to the Company, the results, presented at the 7th International Conference on Complement Therapeutics held on June 6 - 11, 2014, in Olympia, Greece, showed that ALN-CC5 led to an up to 98.7% knockdown of serum C5 and an up to 96.8% inhibition of complement activity in non-human primates (NHP) with weekly subcutaneous dose administration. The Company stated that it is on track to file its ALN-CC5 IND or IND equivalent in late 2014, and expects to present initial clinical results in mid-2015. The full analyst notes on Alnylam are available to download free of charge at:
http://www.analystsreview.com/Jun-12-2014/ALNY/report.pdf
--
Celldex Therapeutics, Inc. Analyst Notes
On June 2, 2014, Celldex Therapeutics, Inc. (Celldex) announced results from its ongoing Phase 1 study of varlilumab (CDX-1127) in cancer. The Company reported that the preclinical data, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 on June 2, 2014, showed that varlilumab is well tolerated and was able to demonstrate clear biologic activity and promising signs of clinical activity in advanced, treatment-refractory patient populations, which provide the rationale for combination studies with other immune activating therapies. "Varlilumab's minimal toxicity and ability to specifically activate the immune system while acutely reducing measurable regulatory T cells make it an ideal agent to use with checkpoint inhibition and other anti-tumor approaches," said Tom Davis, MD, Senior Vice President and Chief Medical Officer of Celldex. According to the Company, Varlilumab will enter at least four combination studies in H2 2014. The full analyst notes on Celldex are available to download free of charge at:
http://www.analystsreview.com/Jun-12-2014/CLDX/report.pdf
--
Keryx Biopharmaceuticals Inc. Analyst Notes
On June 9, 2014, Keryx Biopharmaceuticals Inc. (Keryx) stock increased 6.06% to end the day at $14.52. The Company's stock gained 7.64% over the past three trading days compared to the Nasdaq Composite which rose 1.99% during the same trading period. The full analyst notes on Keryx are available to download free of charge at:
http://www.analystsreview.com/Jun-12-2014/KERX/report.pdf
--
Spectrum Pharmaceuticals, Inc. Analyst Notes
On May 28, 2014, Spectrum Pharmaceuticals, Inc. (Spectrum) announced that it has successfully completed the patient enrollment in the Phase 2 Trial of SPI-2012. SPI-2012 is a long-acting granulocyte stimulating factor developed using LAPSCOVERY technology for the treatment of Chemotherapy-induced Neutropenia. Rajesh C. Shrotriya, MD, Chairman and CEO of Spectrum said, "Pre-clinical and Phase 1 studies have demonstrated that SPI-2012 may have advantages regarding its potency and duration of neutrophil recovery compared to pegfilgrastim. After several years of early stage research, we are now getting closer to evaluating important mid-stage clinical results from SPI-2012. Based on these results, we look forward to making a Phase 3 Go/No-Go decision on SPI-2012 before the end of the year." The Company added that there is a large commercial opportunity as the worldwide market for neutropenia treatments totals over $6 billion. The full analyst notes on Spectrum are available to download free of charge at:
http://www.analystsreview.com/Jun-12-2014/SPPI/report.pdf
--
MacroGenics, Inc. Analyst Notes
On May 27, 2014, MacroGenics, Inc. (MacroGenics) announced that it has formed a strategic alliance with Takeda Pharmaceutical Company Limited (Takeda) for the development and commercialization of MGD010. The Company stated that under the terms of the agreement, MacroGenics will receive an upfront payment of $15 million and Takeda receives an option to obtain exclusive worldwide license for MGD010 following the completion of a pre-defined Phase 1a study. "We are delighted to enter into this collaboration with Takeda. This partnership represents our fifth DART collaboration and MGD010 represents the first autoimmune DART program planned for clinical development," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "As a leading global pharmaceutical company, Takeda brings extraordinary expertise in the autoimmune area with significant capabilities in developing and delivering novel medicines to patients. This collaboration will enable us to further broaden and accelerate our pipeline of innovative DART-based product candidates." The full analyst notes on MacroGenics are available to download free of charge at:
http://www.analystsreview.com/Jun-12-2014/MGNX/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article